Protein Expression

Boston Molecules established proprietary recombinant protein technology for mammalian expression with features:

  • HEK293 mammalian expression platform integrated with chaperone-assisted
    protein expression technology
  • Proper folding, disulfide bonding, and N-linked glycosylation.
  • Low endotoxin <0.10 EU per 1 μg of the protein
  • Average protein activity ~ 5-10 fold higher than R&D system and PeproTech.